ADC	Antibody–drug conjugate
BsAb	Bispecific antibody
CTLA4	Cytotoxic T-lymphocyte-associated protein 4
DAR	Drug–antibody ratio
Dato-DXd	Datopotamab Deruxtecan
DLL3	Delta-like Ligand 3
EGFR	Epidermal growth factor receptor
HER2	Human epidermal growth factor receptor 2
HER3	Human epidermal growth factor receptor 3
HER3-DXd	Patritumab-deruxtecan
ICI	Immune checkpoint inhibitor
ILD	Interstitial lung disease
irAE	Immune-related adverse event
ITT	Intention to treat
LAG3	Lymphocyte-activation gene 3
NSCLC	Non-small cell lung cancer
ORR	Objective response rate
OS	Overall survival
PD1	Programmed cell death protein 1
PDL1	Programmed death-ligand 1
PFS	Progression-free survival
SCLC	Small cell lung cancer
SG	Sacituzumab Govitecan
TCR	T-cell receptor
TROP2	Trophoblast Cell Surface Antigen 2
T-DM1	Trastuzumab Emtansine
T-DXd	Trastuzumab Deruxtecan
TIGIT	T cell immunoreceptor with Ig and ITIM domains
TKI	Tyrosine Kinase Inhibitor